C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis  by unknown
Articles
132 www.thelancet.com   Vol 375   January 9, 2010
C-reactive protein concentration and risk of coronary heart 
disease, stroke, and mortality: an individual participant 
meta-analysis
The Emerging Risk Factors Collaboration*
Summary
Background Associations of C-reactive protein (CRP) concentration with risk of major diseases can best be assessed 
by long-term prospective follow-up of large numbers of people. We assessed the associations of CRP concentration 
with risk of vascular and non-vascular outcomes under diﬀ erent circumstances.
Methods We meta-analysed individual records of 160 309 people without a history of vascular disease (ie, 1·31 million 
person-years at risk, 27 769 fatal or non-fatal disease outcomes) from 54 long-term prospective studies. Within-study 
regression analyses were adjusted for within-person variation in risk factor levels.
Results Loge CRP concentration was linearly associated with several conventional risk factors and inﬂ ammatory 
markers, and nearly log-linearly with the risk of ischaemic vascular disease and non-vascular mortality. Risk ratios 
(RRs) for coronary heart disease per 1-SD higher loge CRP concentration (three-fold higher) were 1·63 
(95% CI 1·51–1·76) when initially adjusted for age and sex only, and 1·37 (1·27–1·48) when adjusted further for 
conventional risk factors; 1·44 (1·32–1·57) and 1·27 (1·15–1·40) for ischaemic stroke; 1·71 (1·53–1·91) and 1·55 
(1·37–1·76) for vascular mortality; and 1·55 (1·41–1·69) and 1·54 (1·40–1·68) for non-vascular mortality. RRs were 
largely unchanged after exclusion of smokers or initial follow-up. After further adjustment for ﬁ brinogen, the 
corresponding RRs were 1·23 (1·07–1·42) for coronary heart disease; 1·32 (1·18–1·49) for ischaemic stroke; 1·34 
(1·18–1·52) for vascular mortality; and 1·34 (1·20–1·50) for non-vascular mortality. 
Interpretation CRP concentration has continuous associations with the risk of coronary heart disease, ischaemic 
stroke, vascular mortality, and death from several cancers and lung disease that are each of broadly similar size. The 
relevance of CRP to such a range of disorders is unclear. Associations with ischaemic vascular disease depend 
considerably on conventional risk factors and other markers of inﬂ ammation. 
Funding British Heart Foundation, UK Medical Research Council, BUPA Foundation, and GlaxoSmithKline.
Introduction
C-reactive protein (CRP), a plasma protein synthesised by 
the liver, is a sensitive and dynamic systemic marker of 
inﬂ ammation.1 Its concentration in the circulation can 
increase by up to 10 000-fold during acute responses to 
serious infection or major tissue damage.2 In the absence 
of such spikes, however, the year-to-year within person 
variations in CRP concentration are similar to those in 
total cholesterol concentration and systolic blood pressure.3 
The stability of this protein during long-term frozen blood 
storage and availability of standardised assays have assisted 
studies of CRP.4–8 Aside from whether measurement of 
CRP is useful in assessment of vascular risk,4,9 studies are 
needed to help ﬁ nd out if CRP is a mediator of vascular 
disease.10,11 CRP binds to LDL12,13 and is present in athero-
sclerotic plaques,14 so it has been proposed that CRP may 
have a causal role in coronary heart disease. In a literature-
 based meta-analysis7 of 22 prospective studies, the relative 
risk for coronary heart disease was 1·6 (95% CI 1·5–1·7) in 
a comparison of people in the top third (mean 2·4 mg/L) 
and bottom third (1·0 mg/L) of the CRP distribution. 
To help judge the likelihood of causality, information is 
needed about the extent to which disease associations with 
CRP concentrations are independent of conventional risk 
factors.7 Previous studies were not adequately powered to 
assess whether CRP concentration is associated with 
diﬀ erent stroke subtypes,15–17 and whether concentration is 
associated exclusively with vascular disease or also with 
non-vascular diseases.18 The shape of the dose-response 
association between CRP concentration and the risk of 
vascular and non-vascular diseases has not been well 
characterised. Furthermore, powerful analyses are needed 
to ﬁ nd out whether the strength of association of CRP 
concentration and risk of disease varies by age, sex, or 
other clinically relevant subgroups.18 We therefore assessed 
the independence, speciﬁ city, magnitude, and shape of 
associations of CRP concentration with vascular and non-
vascular outcomes under diﬀ erent circumstances.
Methods
Study design
Details of study selection, and data collation and harmo-
nisation in the Emerging Risk Factors Collaboration 
have been described previously.19 Investigators from 
116 prospective studies of cardiovascular risk factors, with 
a total of 1·2 million participants, shared individual 
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records. In these studies, participants were not selected on 
the basis of having previously had cardiovascular disease; 
vascular morbidity and cause-speciﬁ c mortality were 
recorded on the basis of clearly deﬁ ned criteria; and 
accrued follow-up was more than 1 year. Analyses were 
restricted to participants without any known history of 
cardio vascular disease (ie, myocardial infarction, angina, 
or stroke deﬁ ned according to study criteria). Information 
about CRP concen tration, age, sex, and other conventional 
vascular risk factors was available in 54 studies, with a total 
of 160 309 participants with 27 769 ﬁ rst-ever non-fatal or 
fatal vascular and non-vascular disease outcomes 
(webappendix p 2 and p 15). Baseline information was not 
available for non-vascular diseases. Complete information 
was available for CRP concentration, age, sex, systolic 
blood pressure, smoking habits, history of diabetes 
mellitus (type 1 or 2, though usually not speciﬁ ed), 
body-mass index, and con centrations of triglycerides and 
total cholesterol in 109 742 participants from 37 studies. 
High-sensitivity CRP assays were used in 52 of 54 studies. 
The CRP standards used were identiﬁ ed in 43 studies 
(webappendix p 4). International Classiﬁ cation of Diseases 
codings (to at least three numbers) were used to register 
fatal diseases, which were ascertained from information 
provided on death certiﬁ cates (webappendix p 6). Medical 
records, autopsy ﬁ ndings, and other supplementary 
sources were used to help classify deaths in 41 of 54 studies. 
Standard deﬁ nitions of myocardial infarction based on 
Monitoring Trends and Determinants in Cardiovascular 
Disease (MONICA) or WHO criteria were reported in 
49 studies.20 Diagnosis of stroke on the basis of typical 
clinical features and characteristic changes on brain 
imaging was reported in 40 studies, enabling attribution of 
stroke types (eg, cerebral ischaemia, cerebral haemorrhage, 
or sub arach noid haemorrhage).
The study was approved by an ethics review committee 
in Cambridgeshire, UK.
Statistical analyses
Details of the statistical methods have been previously 
provided.21 Normal distributions were obtained with 
natural logarithm (loge) transformation of positively 
skewed variables, including CRP concentration. The 
pooled SD for baseline loge CRP concentration was 1·11, 
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Figure 1: Geometric mean C-reactive protein (CRP) concentration in men and women according to cohort and assay source (A) and within 5-year bands adjusted for cohort (B)
Data from the third National Health and Nutrition Examination Survey (NHANESIII) and Population Study of Women in Göteborg (GOTOW) are not represented in the graph because they did not use 
high sensitivity CRP assays.19 NS=not stated. Error bars represent the 95% CIs.
See Online for webappendix
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which corresponds to a three-fold diﬀ erence (ie, e¹·¹¹) in 
mg/L on the original scale of CRP measurement. Sex-
speciﬁ c associations of CRP with various risk factors 
were assessed, using a linear mixed model adjusted for 
age.22 The primary outcome was coronary heart disease 
(ie, ﬁ rst-ever myocardial infarction or fatal coronary heart 
disease), with subsidiary analyses of stroke by subtype, 
death from vascular disease, and aggregate of non-vascular 
death (with subdivisions modelled on the approach of a 
previous study23). Only ﬁ rst non-fatal vascular outcomes 
or deaths recorded at age 40 years or older were included 
in the primary analysis (ie, deaths preceded by non-fatal 
coronary heart disease or stroke were not included in the 
analyses). We did a subsidiary analysis for fatal outcomes 
without censoring for previous non-fatal outcomes. 
Analyses involved a two-stage approach with estimates of 
association calculated separately within each study before 
data from diﬀ erent studies were pooled by use of 
random-eﬀ ects meta-analysis. We used ﬁ xed-eﬀ ect 
models for parallel analyses. For the 42 studies analysed 
as prospective cohorts, hazard ratios were calculated with 
Cox proportional hazards regression stratiﬁ ed by sex 
(and, when appropriate, by trial group). The assumptions 
for the proportionality of hazards were met. For the 
12 case-control studies nested within prospective cohorts, 
odds ratios were calculated with conditional or 
unconditional logistic regression models, as appropriate. 
Hazard ratios and odds ratios were assumed to represent 
nearly the same relative risk and are collectively described 
as risk ratios (RRs). As directly measured concentrations 
of LDL-cholesterol were available for 48 475 participants, 
the concentration of non-HDL cholesterol was used as 
the main marker of cholesterol content in proatherogenic 
lipoproteins rather than that of LDL-cholesterol estimated 
with the Friedewald formula.24,25
Study-speciﬁ c RRs were calculated within overall 
quantiles of baseline concentrations of CRP, and were 
combined on the log scale by use of multi variate random-
eﬀ ects meta-analysis, and plotted against pooled mean 
usual concentrations within each quantile. 95% CIs were 
estimated from variances attributed to the groups to 
reﬂ ect the amount of information within each group 
(including the reference group). When associations were 
nearly log-linear, regression coeﬃ  cients were calculated 
to estimate the RR associated with a 1-SD higher 
loge CRP (1·11 loge mg/L, corresponding to a three-fold 
higher concentration). RRs were adjusted progressively 
for age, sex, and several other conventional risk factors, 
with the evidence of association indicated by the Wald χ² 
statistic.23 The sequence of introduction of variables into 
the model followed the example of a previous report.23 To 
help distinguish whether CRP concentration or 
inﬂ ammatory processes in general might be relevant to 
disease risk, we also adjusted for other circulating markers 
of inﬂ ammation (such as ﬁ brinogen). I² statistic was used 
as a measure of consistency across studies—ie, the 
percentage of variance in estimated loge RRs that was 
attributable to between study variation as opposed to 
sampling variation. Values of I² close to 0 correspond to 
lack of heterogeneity. We investigated diversity at the 
study level by grouping studies according to recorded 
charac teristics and meta-regression. 
We corrected concurrently for regression dilution in 
CRP concentration and in potential confounding factors.26,27 
Regression dilution ratios for each charac teristic were 
calculated with regression of serial measure ments on 
baseline concentrations, adjusted for con ven tional risk 
factors plus baseline loge CRP concen tration and duration 
of follow-up.26,27 Correction for within- person variation in 
CRP concentration and potential confounders was achieved 
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Figure 2: Cross-sectional associations between geometric mean C-reactive protein (CRP) concentration and 
some conventional risk factors and other characteristics
Mean CRP concentration was adjusted to age 50 years. Error bars represent the 95% CIs. BP=blood pressure. 
r=Pearson’s correlation coeﬃ  cient (95% CI) for association between the risk marker and loge CRP concentration in 
men and women combined.
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by use of conditional expecta tions of long-term average 
(usual) concentrations of CRP and con founders predicted 
from regression calibration models,27 and used in 
assessments of associations with disease risk. For analyses 
we used Stata (version 10.0). 
Role of the funding source
SK and JD had full access to all data in the study and had 
ﬁ nal responsibility to submit the report for publication. 
The study was conducted and analysed independently 
from its funders.
Results
Mean age of participants at entry into the study was 
60 years (SD 8); 76 171 (48%) were women; and 78 619 (49%) 
were European and 75 919 (47%) were North American. 
During 1·31 million person-years at risk (median 
5·8 years to ﬁ rst outcome, IQR 2·5–9·5), there were 
10 451 coronary heart disease outcomes (7381 non-fatal 
myocardial infarctions and 3070 deaths from coronary 
diseases), 2846 ischaemic strokes, 469 haemorrhagic 
strokes, 1180 unclassiﬁ ed strokes, and 1659 deaths from 
other vascular diseases, 10 236 from non-vascular diseases, 
and 860 from unknown causes. Mean loge CRP 
concentration varied between studies and increased with 
age (ﬁ gure 1), but SDs were generally similar between 
studies (webappendix p 2). The overall median for 
baseline CRP concentration was 1·72 mg/L (5th percentile 
0·25, 95th percentile 12·4).
CRP concentration was positively correlated with con-
centrations of non-HDL cholesterol, loge triglycerides, 
ﬁ brinogen, and interleukin 6, systolic blood pressure, 
body-mass index, and loge leucocyte count; and inversely 
with concentrations of HDL cholesterol and albumin 
(ﬁ gure 2). CRP concentration was higher in women than 
in men, in smokers than in non-smokers, and in people 
with diabetes than in those without, and was lower in 
alcohol drinkers than in non-drinkers and in physically 
active people than in those not physically active (ﬁ gure 2; 
webappendix p 8). More than one CRP measurement 
was available in 22 124 participants with 24 222 serial 
measurements (mean interval 5·1 years, SD 2·4; 
webappendix p 16). The regression-dilution ratio of loge 
CRP concentration, adjusted for age and sex, was 0·58 
(95% CI 0·52–0·63), indicating a year-to-year consistency 
that was generally similar to that for systolic blood 
pressure (0·54, 0·51–0·58), and concentrations of total 
cholesterol (0·59, 0·54–0·64), HDL cholesterol (0·74, 
0·70–0·78), and ﬁ brinogen (0·51, 0·46–0·56) in the 
same individuals.
In analyses adjusted for age and sex only, associations 
of loge CRP concentration with the risk of coronary heart 
disease and ischaemic stroke were nearly log-linear, with 
no obvious risk thresholds (ﬁ gure 3A). The corresponding 
associations of CRP concentration with all vascular 
mortality and with all non-vascular mortality seemed 
curvilinear. RR for coronary heart disease, adjusted for 
age and sex only, per 1-SD higher usual loge CRP 
concentration (ie, three-fold higher CRP concentration) 
was 1·68 (95% CI 1·59–1·78), with the RR possibly 
higher for fatal (1·84, 1·59–2·14) than for non-fatal 
myocardial infarction (1·59, 1·45–1·75; p=0·04; 
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Figure 3: Risk ratios for major vascular and non-vascular outcomes by quantiles of C-reactive protein (CRP) 
concentration, with diﬀ erent degree of adjustment for potential confounders
Adjusted study-speciﬁ c loge risk ratios were combined by use of multivariate random-eﬀ ects meta-analysis. 
The adjustments were age, sex, and study only (A); age, sex, study, systolic blood pressure, smoking, history of 
diabetes, body-mass index, concentrations of loge triglycerides, non-HDL cholesterol, and HDL cholesterol, and 
alcohol consumption (B); and (A) plus (B) plus ﬁ brinogen (C). Studies with fewer than ten cases of any outcome 
were excluded from the analysis of that outcome. Error bars represent the 95% CIs, calculated using ﬂ oating 
absolute risk technique. The sizes of the boxes are proportional to the inverse of the variance of the risk ratios.
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webappendix p 9). For all strokes combined, the 
corresponding RR was 1·39 (1·29–1·51), with RRs of 
1·46 (1·32–1·61) for ischaemic stroke, 1·07 (0·86–1·32) 
for haemorrhagic stroke, and 1·41 (1·22–1·63) for 
unclassiﬁ ed stroke. Figure 4 shows the RRs for all deaths 
from vascular and non-vascular causes. CRP con-
centration was sig niﬁ  cantly associated with a range of 
diﬀ erent conditions, including several cancers, lung 
diseases, and even external causes. There were generally 
too few cases of site-speciﬁ c cancer mortality to enable 
reliable analyses. RRs were generally similar in analyses 
that excluded current smokers or were restricted to 
participants with ﬁ rst outcomes recorded after the ﬁ rst 
5 years of follow-up (webappendix p 18).
In analyses involving adjustment for additional risk 
factors, RR for coronary heart disease was reduced after 
adjustment for age, sex, systolic blood pressure, smoking, 
history of diabetes, body-mass index, and concentrations 
of triglycerides and total cholesterol (table 1). Further 
adjustment for concentrations of non-HDL cholesterol 
and HDL cholesterol, and alcohol consumption, resulted 
in a further reduction in RR and in the corresponding 
Wald χ² statistic (table 1; ﬁ gure 3B). Adjusted RRs for 
coronary heart disease per 1-SD higher levels of each risk 
factor were 1·37 (95% CI 1·27–1·48) with CRP con-
centration, 1·28 (1·16–1·40) with non-HDL-cholesterol 
concentration, and 1·35 (1·25–1·45) with systolic blood 
pressure (webappendix p 19). The RRs with CRP were 
1·55 (1·37–1·76) for vascular mortality and 1·54 
(1·40–1·68) for non-vascular mortality after adjustment 
of con ventional risk factors (webappendix p 10). 
Figure 3C and table 2 show RRs for coronary heart 
disease and ischaemic stroke after further adjustment for 
ﬁ brinogen (or other markers of inﬂ ammation). In 
participants with complete information available for CRP 
concentration, conventional risk factors, and ﬁ brinogen 
concentration, RR for coronary heart disease associated 
with CRP after adjustment for conventional risk factors 
was reduced from 1·36 (95% CI 1·22–1·52) to 1·23 
(1·07–1·42) after further adjustment for ﬁ brinogen (Wald 
χ² was reduced from 29 to 8; table 2). By comparison, the 
corresponding adjusted RR for coronary heart disease 
was 1·21 (1·08–1·35) per 1-SD higher usual ﬁ brinogen 
after adjustment for several conventional risk factors and 
CRP concentration. RR for ischaemic stroke associated 
with CRP after adjustment for conventional risk factors 
did not diﬀ er after further adjustment for ﬁ brinogen 
(table 2). RR for non-vascular death was 1·52 (1·37–1·69) 
with CRP concentration after adjustment for conventional 
risk factors, and 1·34 (1·20–1·50; webappendix p 11) after 
further adjustment for ﬁ brinogen. When ﬁ brinogen was 
replaced with another marker of inﬂ ammation (eg, 
leucocyte count) in the model, reduction in the RRs with 
CRP was slightly smaller (albeit based on fewer data). 
Since only about 10% of individuals had concomitant 
data for CRP concentration, conventional risk factors, 
ﬁ brinogen concentration, and at least one other 
inﬂ ammatory marker, more detailed adjustment for 
inﬂ ammation was not possible.
There may have been heterogeneity between studies in 
RRs for coronary heart disease (I²=26%, 95% CI 0–53). 
Apart from possibly higher RRs in men than in women 
(p=0·015), RRs for coronary heart disease did not vary in 
clinically relevant subgroups—such as people with 
diabetes, increased concentrations of lipids, and obesity, 
or in smokers—or with other participant or study 
characteristics (webappendix pp 20–21), or in exploratory 
analyses of individuals with morbid obesity or very high 
concentrations of lipids (webappendix p 20). Likewise, 
evidence of heterogeneity between studies in RRs for 
ischaemic stroke was not clear (I²=0, 0–54). Qualitatively 
similar results to those reported here were noted in 
analyses that did not correct for regression dilution; 
adjusted for smoking amount (webappendix p 12); used 
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ﬁ xed-eﬀ ect models (webappendix p 13); included fatal 
outcomes without censoring previous non-fatal outcomes 
(webappendix p 14); excluded the two studies in which 
high-sensitivity CRP assays were not used; compared 
larger versus smaller studies (webappendix p 24); and 
excluded  the 10 188 partici pants with CRP values greater 
than 10 mg/L.
Discussion
The current study has shown that CRP concentration is 
as consistent within individuals during several years as 
are total cholesterol concentration and systolic blood 
pressure. In individuals without initial vascular disease, 
associations of CRP concentration with subsequent risk 
of coronary heart disease, ischaemic stroke, and deaths 
from vascular and non-vascular diseases (including 
several cancers and respiratory diseases) were generally 
log-linear in shape. These associations persisted in 
analyses in which smokers and the initial years of 
follow-up were excluded. 
Associations of CRP with vascular and non-vascular 
outcomes were each of broadly similar size. These 
ﬁ ndings resemble results previously reported with other 
downstream markers of inﬂ ammation, notably ﬁ brinogen 
concentration,23 leucocyte count,28 albumin con cen-
tration,28 or erythrocyte sedimentation rate.29 Like CRP, 
each of these factors is modulated by mediators of 
inﬂ ammatory cascades (eg, interleukin 6), and our data 
conﬁ rm that such inﬂ ammatory markers are associated 
with CRP. Although persistent low-grade inﬂ ammation 
is proposed to be relevant to vascular and malignant 
diseases,30 the mechanisms are not known. The 
associations that we noted between CRP concentration 
and death from external causes (eg, injury) might be 
attributed, at least in part, to confounding by comorbidity 
at baseline.
Adjustment for several conventional risk factors and 
plasma ﬁ brinogen (also an acute phase reactant protein 
synthesised in the liver and modulated by inter leukin 623,31,32) 
resulted in considerable weakening of associations of CRP 
concentration with risk of coronary heart disease. Such 
adjustment also attenuated associations of CRP 
concentration with ischaemic stroke and deaths from 
non-vascular diseases. Hence, although our results 
support the idea that some process related to persistent 
inﬂ ammation is associated with vascular disease and other 
Basic adjustment* Further adjustment*
RR† (95% CI) usual loge 
CRP concentration
Wald χ21 I2 (95% CI) RR† (95% CI) usual loge 
CRP concentration
Wald χ21 I2 (95% CI)
Coronary heart disease‡
Adjusted for age, sex, and study 1·64 (1·54–1·75) 231 44% (17–62) 1·63 (1·51–1·76) 149 51% (26–68)
Plus systolic blood pressure 1·57 (1·48–1·67) 201 37% (7–58) 1·55 (1·44–1·67) 134 42% (12–62)
Plus smoking 1·50 (1·41–1·59) 181 26% (0–51) 1·48 (1·38–1·59) 123 30% (0–55)
Plus history of diabetes 1·45 (1·36–1·55) 121 38% (7–58) 1·43 (1·32–1·55) 78 42% (10–62)
Plus body-mass index 1·46 (1·37–1·55) 137 22% (0–48) 1·45 (1·34–1·56) 85 31% (0–56)
Plus loge triglycerides concentration 1·41 (1·32–1·51) 103 26% (0–51) 1·40 (1·29–1·52) 64 35% (0–58)
Plus total cholesterol concentration 1·42 (1·33–1·52) 110 24% (0–50) 1·41 (1·30–1·53) 69 33% (0–57)
Plus non-HDL cholesterol concentration§ ·· ·· ·· 1·40 (1·30–1·51) 74 26% (0–53)
Plus HDL cholesterol concentration§ ·· ·· ·· 1·39 (1·28–1·49) 71 25% (0–52)
Plus alcohol consumption§ ·· ·· ·· 1·37 (1·27–1·48) 65 26% (0–53)
Ischaemic stroke¶
Adjusted for age, sex, and study 1·43 (1·32–1·55) 80 0 (0–51) 1·44 (1·32–1·57) 68 7% (0–57)
Plus systolic blood pressure 1·34 (1·23–1·45) 50 0 (0–51) 1·33 (1·23–1·45) 46 0 (0–54)
Plus smoking 1·31 (1·20–1·42) 40 0 (0–51) 1·31 (1·20–1·42) 38 0 (0–54)
Plus history of diabetes 1·25 (1·14–1·35) 26 0 (0–51) 1·24 (1·14–1·36) 25 0 (0–54)
Plus body-mass index 1·29 (1·18–1·41) 29 0 (0–51) 1·29 (1·18–1·42) 28 0 (0–54)
Plus loge triglycerides concentration 1·27 (1·16–1·40) 26 0 (0–51) 1·27 (1·15–1·40) 24 0 (0–54)
Plus total cholesterol concentration 1·28 (1·17–1·41) 27 0 (0–51) 1·28 (1·16–1·40) 25 0 (0–54)
Plus non-HDL cholesterol concentration§ ·· ·· ·· 1·28 (1·16–1·40) 25 0 (0–54)
Plus HDL cholesterol concentration§ ·· ·· ·· 1·27 (1·16–1·40) 25 0 (0–54)
Plus alcohol consumption§ ·· ·· ·· 1·27 (1·15–1·40) 24 0 (0–54)
*Analyses were restricted to participants with complete information available for sex, trial group, and all confounding variables; studies with fewer than ten cases were 
excluded from the analysis of each outcome. †Per 1·11 higher loge CRP (ie, 1-SD ), corresponding to a three-fold higher CRP concentration, progressively adjusted and 
stratiﬁ ed when appropriate by sex and trial group. ‡Basic adjustment: 37 studies, 109 742 participants, and 8056 events; further adjustment: 31 studies, 91 990 participants, 
and 5373 events. §Non-HDL cholesterol has been substituted for total cholesterol in these adjusted models. ¶Basic adjustment: 17 studies, 65 825 participants, and 2006 
events; further adjustment: 15 studies, 60 763 participants, and 1931 events.
Table 1: Risk ratios (RRs) for coronary heart disease and ischaemic stroke per three-fold higher usual C-reactive protein (CRP) concentration with 
progressive adjustment for usual levels of potential confounders
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chronic disorders, most of the association with ischaemic 
vascular disease depends on conventional risk factors and 
ﬁ brinogen concen tration.29,31–34 If ﬁ brinogen mediates the 
association between CRP concentration and risk of 
coronary heart disease, then correction for ﬁ brinogen 
could be an overadjustment. 
In studies in which CRP-related genotypes are proxies 
for life-long CRP concentration (ie, Mendelian ran dom-
isation analyses), such diﬃ  culties in interpretation should 
be avoided, provided the genotypes are not correlated with 
ﬁ brinogen. In previous analyses, in cluding a study of 
28 000 patients with coronary heart disease and 
100 000 controls,35 null associations were reported between 
CRP-related genotypes and ﬁ brinogen concentration,36 
conventional risk factors,37 and risk of coronary heart 
disease.36,38,39 Hence, our ﬁ ndings—taken with available 
genetic data—reduce the likelihood of causality for CRP 
in coronary heart disease. Results from randomised trials 
have shown that statins reduce concentrations of CRP in 
healthy individuals and in those with stable vascular 
disease.40 Rosuvastatin reduced the risk of ﬁ rst-ever 
vascular disease in individuals who had lower-than-average 
LDL-cholesterol concentration and higher-than-average 
CRP concentration.41 But, since statins potently aﬀ ect 
LDL-cholesterol concentration (an established causative 
risk factor in coronary disease), studies of these drugs 
cannot provide speciﬁ c causal inferences about CRP 
concentration. Immuno suppressant or anti-inﬂ ammatory 
drugs, or vaccination, have not yet been adequately 
studied as prophylactic interventions to test the 
inﬂ ammation hypothesis.32
This meta-analysis diﬀ ers from previous reports in 
several important ways. First, it was larger and more 
comprehensive. Second, use of individual participant 
data enabled a consistent approach to adjustment for 
potential confounders and exploration of subgroups. 
Third, associations were corrected for measurement 
error and within-person variation (ie, regression 
dilution26,27,42), using information from 22 124 participants 
with serial measurements. Fourth, individuals with a 
history of coronary heart disease or stroke were excluded, 
reducing any eﬀ ects of clinically evident disease on CRP 
concentration. Although there was heterogeneity in the 
ﬁ ndings in relation to coronary heart disease (no greater 
in extent to that seen with non-HDL-cholesterol con-
centration in the same studies25), little of it could be 
attributed to the recorded characteristics. Since most 
disease outcomes were recorded among white 
participants, the ﬁ ndings do not necessarily apply to 
non-white individuals. Our results conﬁ rm that CRP 
concentration can diﬀ er substantially in diﬀ erent ethnic 
groups (eg, concentrations were 26% higher in black 
individuals and 16% lower in east Asian individuals than 
in white people).43
Large studies are needed that concurrently assess 
several proximal (eg, interleukin 6) and distal (eg, CRP, 
ﬁ brinogen) markers of inﬂ ammation, and markers of 
rupture-prone plaque (eg, lipoprotein-associated phospho-
lipase A244), as well as their genetic and lifestyle 
determinants. Further work is also needed to assess 
whether evidence of low-grade inﬂ ammation mainly 
indicates external triggers (eg, socioeconomic position or 
infection), insulin resistance, hereditary predisposition, 
or some combination of such factors.45–47
In subsequent analyses from this collaboration, we will 
assess CRP concentration for the prediction of 
vascular disease—a separate issue requiring analytical 
approaches that are diﬀ erent from those used in this 
meta- analysis.48–50 
Studies Outcomes RR* (95% CI) usual loge 
CRP concentration
Wald χ²1 I² (95% CI)
Coronary heart disease
Adjusted for age, sex, and study 
(n=66 117)
20 3062 1·65 (1·48–1·84) 80 57% (30–74)
Plus conventional risk factors† 20 3062 1·36 (1·22–1·52) 29 36% (0–63)
Plus ﬁ brinogen 20 3062 1·23 (1·07–1·42) 8 57% (30–74)
Adjusted for age, sex, and study 
(n=32 958)
12 2689 1·66 (1·48–1·86) 78 52% (7–75)
Plus conventional risk factors† 12 2689 1·44 (1·29–1·62) 40 35% (0–67)
Plus albumin 12 2689 1·38 (1·26–1·51) 47 15% (0–54)
Adjusted for age, sex, and study 
(n=21 917)
11 2688 1·68 (1·48–1·91) 65 60% (22–79)
Plus conventional risk factors† 11 2688 1·42 (1·26–1·60) 32 37% (0–69)
Plus loge leucocyte count 11 2688 1·30 (1·16–1·45) 20 36% (0–68)
Adjusted for age, sex, and study 
(n=19 016)
7 1547 1·77 (1·37–2·28) 19 83% (67–91)
Plus conventional risk factors† 7 1547 1·42 (1·15–1·74) 11 59% (5–82)
Plus loge interleukin 6 7 1547 1·19 (1·01–1·41) 4 31% (0–70)
Ischaemic stroke
Adjusted for age, sex, and study 
(n=47 353)
11 1481 1·49 (1·34–1·67) 49 16% (0–57)
Plus conventional risk factors† 11 1481 1·32 (1·18–1·47) 24 0 (0–60)
Plus ﬁ brinogen 11 1481 1·32 (1·18–1·49) 22 0 (0–60)
Adjusted for age, sex, and study 
(n=19 382)
6 890 1·37 (1·23–1·52) 35 0 (0–75)
Plus conventional risk factors† 6 890 1·28 (1·14–1·44) 16 0 (0–75)
Plus albumin 6 890 1·21 (1·07–1·35) 10 0 (0–75)
Adjusted for age, sex, and study 
(n=14 076)
7 1252 1·40 (1·26–1·55) 42 0 (0– 71)
Plus conventional risk factors† 7 1252 1·25 (1·11–1·41) 13 0 (0–71)
Plus loge leucocyte count 7 1252 1·15 (1·02–1·29) 5 0 (0–71)
Adjusted for age, sex, and study 
(n=9918)
3 480 1·63 (1·15–2·29) 8 63% (0–89)
Plus conventional risk factors† 3 480 1·47 (1·09–1·98) 6 42% (0–83)
Plus loge interleukin 6 3 480 1·18 (0·98–1·41) 3 0 (0–90)
Analyses were restricted to participants with complete information about sex, trial group, and all the conventional risk 
factors plus each inﬂ ammatory marker. Studies with fewer than ten cases were excluded from the analysis of each 
outcome. Data are number, unless otherwise indicated. *Per 1·11 higher loge CRP (ie, 1-SD), corresponding to a 
three-fold higher CRP concentration, progressively adjusted and stratiﬁ ed (when appropriate) by sex and trial group. 
†Age, sex, systolic blood pressure, smoking, history of diabetes, body-mass index, concentrations of loge triglycerides, 
non-HDL cholesterol, and HDL cholesterol, and alcohol consumption.
Table 2: Risk ratios (RRs) for coronary heart disease and ischaemic stroke per three-fold higher usual 
C-reactive protein (CRP) concentration with adjustment for usual levels of conventional risk factors plus 
diﬀ erent inﬂ ammatory markers
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